Published in Cancer Weekly, March 7th, 2006
"Tumor-derived COX-2 and its product, prostaglandin E-2, exert strong immunoinhibitory effects that block dendritic cell function and CD4+ and CD8+ T-cell proliferation and function. We have shown previously that the addition of an oral COX-2 inhibitor to immunogene therapy using IFN-beta markedly augmented therapeutic efficacy in murine tumor models."
"In this study," wrote A.R. Haas and colleagues, Thoracic Oncology Research Laboratory, "we hypothesized that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.